Therapeutic agents for the treatment and prevention of Alzheimer's.
Alzheimer's Donation
Donate Online Now
.
Intellect Neurosciences, Inc. ("Intellect"), a biopharmaceutical company focused on development of disease- modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and related disorders, announced today that it has entered into an agreement and plan of merger with GlobePan Resources, Inc., a publicly held Delaware corporation ("GlobePan"). Now Intellect will be eligible to seek a public listing for its shares. All of the assets and liabilities of GlobePan were divested by GlobePan prior to the merger. "We are proud to join the ranks of publicly held biotech companies searching for innovative solutions to today's most challenging therapeutic areas and medical frontiers," commented Dr. Daniel Chain, Intellect's Chairman and Chief Executive Officer. "This achievement allows us to better focus our attention on moving forward with our ambitious clinical development plans." "We are excited and proud to have reached this milestone, which is the first step towards enabling our shareholders to access a trading market for our shares and which will allow us to access the public capital markets," commented Intellect's Executive Vice President and CFO, Elliot M. Maza.
Intellect has recently completed Phase I clinical trials for OXIGON(TM), a unique antioxidant and anti-amyloid compound that has potential to treat Alzheimer's disease and other disorders. For additional information, please visit http://www.intellectns.com
Donate Online Now
.
Intellect Neurosciences, Inc. ("Intellect"), a biopharmaceutical company focused on development of disease- modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and related disorders, announced today that it has entered into an agreement and plan of merger with GlobePan Resources, Inc., a publicly held Delaware corporation ("GlobePan"). Now Intellect will be eligible to seek a public listing for its shares. All of the assets and liabilities of GlobePan were divested by GlobePan prior to the merger. "We are proud to join the ranks of publicly held biotech companies searching for innovative solutions to today's most challenging therapeutic areas and medical frontiers," commented Dr. Daniel Chain, Intellect's Chairman and Chief Executive Officer. "This achievement allows us to better focus our attention on moving forward with our ambitious clinical development plans." "We are excited and proud to have reached this milestone, which is the first step towards enabling our shareholders to access a trading market for our shares and which will allow us to access the public capital markets," commented Intellect's Executive Vice President and CFO, Elliot M. Maza.
Intellect has recently completed Phase I clinical trials for OXIGON(TM), a unique antioxidant and anti-amyloid compound that has potential to treat Alzheimer's disease and other disorders. For additional information, please visit http://www.intellectns.com
posted by Valery Yermalitsky at
6:33 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home